ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Authors
Keywords
-
Journal
NATURE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-06
DOI
10.1038/s41586-021-03515-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization
- (2020) Nicholas P. D. Liau et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
- (2020) Jayesh Desai et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
- (2020) Xi Yuan et al. Molecular Oncology
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors
- (2020) Kelli-Ann Monaco et al. CLINICAL CANCER RESEARCH
- Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.
- (2019) Tae Won Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic
- (2019) Savithri Ramurthy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
- (2018) Travis A. Clark et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- SWISS-MODEL: homology modelling of protein structures and complexes
- (2018) Andrew Waterhouse et al. NUCLEIC ACIDS RESEARCH
- CSIG-19. FHL2 INTERACTS WITH EGFRVIII TO PROMOTE GLIOBLASTOMA GROWTH
- (2017) Lili Sun et al. NEURO-ONCOLOGY
- RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma
- (2017) Coralie Dorard et al. Nature Communications
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- (2016) Raphael Bueno et al. NATURE GENETICS
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- (2016) Aaron N Hata et al. NATURE MEDICINE
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers
- (2015) Z. Tang et al. MOLECULAR CANCER THERAPEUTICS
- Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
- (2015) Hyo-eun C Bhang et al. NATURE MEDICINE
- Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
- (2014) Zheng Zhao et al. ACS Chemical Biology
- Somatic activating ARAF mutations in Langerhans cell histiocytosis
- (2014) D. S. Nelson et al. BLOOD
- Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling
- (2014) Jacob R. Haling et al. CANCER CELL
- Ins and Outs of Kinase DFG Motifs
- (2013) Daniel K. Treiber et al. CHEMISTRY & BIOLOGY
- Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
- (2013) D. M. Molina et al. SCIENCE
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- An Optimized microRNA Backbone for Effective Single-Copy RNAi
- (2013) Christof Fellmann et al. Cell Reports
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers
- (2012) A P Rebocho et al. ONCOGENE
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Mutant BRAF Melanomas—Dependence and Resistance
- (2011) Poulikos I. Poulikakos et al. CANCER CELL
- c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
- (2011) Rafael B. Blasco et al. CANCER CELL
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo
- (2011) Kristen L. Meerbrey et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Features and development ofCoot
- (2010) P. Emsley et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- PHENIX: a comprehensive Python-based system for macromolecular structure solution
- (2010) Paul D. Adams et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape
- (2009) Aleksandar Sekulic et al. MAYO CLINIC PROCEEDINGS
- C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E
- (2009) Florian A. Karreth et al. MOLECULAR CELL
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More